Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis | ||
By: Nasdaq / GlobeNewswire - 10 Dec 2018 | Back to overview list |
|
Company also announces first patient enrolled in clinical trial of XHANCE for treatment of nasal polyps in pediatric patients YARDLEY, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced today the enrollment of the first patient in a global clinical trial to evaluate the safety and efficacy of XHANCE® (fluticasone propionate) nasal spray as a treatment for patients with Chronic Sinusitis. The trial is a randomized, double-blind, placebo-controlled study of approximately 400 patients across 50 sites. In addition, the Company announced the enrollment of the first patient in a clinical trial to evaluate the safety and efficacy of XHANCE for treatment of adolescent pediatric patients with nasal polyps. The pediatric trial is a randomized, double-blind, placebo-controlled study of approximately 120 patients across 30 sites. "We are particularly pleased to be initiating our clinical program in pursuit of an indication for treatment of Chronic Sinusitis because we are aware of no approved drugs for that indication, and we believe there is a very large population in need of treatment,” said Dr. Ramy Mahmoud, President and Chief Operating Officer of Optinose. "We anticipate starting the second trial in the program in 2019 and hope to achieve the first ever approval for this indication." About Optinose Cautionary Note on Forward-Looking Statements Optinose Investor Contact |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |